Study guide

9.3 HDFN Pathophysiology & Detection

Specialist in Blood Banking, SBB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB

2 Donors & Collection

2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations

3 Processing, Storage & Component QC

3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control

4 Red Cell & Modified Components

4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes

5 Platelets, Plasma & Cellular Products

5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors

6 Genetics, ABO & Rh

6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii

7 Other Blood Groups & Role in Transfusion

7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence

8 Immunology Foundations

8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement

9 Physiology, Hemostasis & HDFN

9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention

10 Cytopenias & Transplantation

10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation

11 Routine Serologic Testing

11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents

12 Special Serologic Methods

12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid

13 Molecular Platforms & Serologic QA

13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance

14 Indications, Component Therapy & PBM

14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management

15 Adverse Effects of Transfusion

15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases

16 Apheresis & Extracorporeal Circulation

16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation

17 Quality, Safety, Math & Instrumentation

17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation

18 Laboratory Administration (SBB Only)

18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management

9.3 HDFN Pathophysiology & Detection

Key Takeaways Explain This Topic AI

HDFN requires a maternal IgG antibody against a paternally-inherited fetal red cell antigen; only IgG crosses the placenta, so IgM antibodies do not cause HDFN.

Anti-K (Kell) causes severe fetal anemia by suppressing erythropoiesis directly, so its critical titer (1:4) is lower than the conventional 1:16 used for most other antibodies.

ABO HDFN from anti-A/anti-B is usually mild because fetal A/B antigen expression is weak and antigen is also absorbed by other tissues and secretions.

MCA-PSV Doppler surveillance begins by 16-18 weeks once a critical titer is reached, and a value at or above 1.5 MoM signals a high probability of moderate-to-severe fetal anemia warranting cordocentesis.

Last updated: July 2026

9.3 HDFN Pathophysiology & Detection

Quick Answer: Hemolytic disease of the fetus and newborn (HDFN) occurs when a maternal IgG alloantibody crosses the placenta and destroys fetal red cells carrying a paternally-inherited antigen the mother lacks. Anti-D is the classic severe cause; anti-K (Kell) is uniquely severe because it also suppresses fetal erythropoiesis; ABO HDFN from anti-A/anti-B is usually mild. Detection combines maternal antibody screening and titers, fetal antigen genotyping, and middle cerebral artery Doppler studies (MCA-PSV) to identify fetal anemia before it becomes life-threatening.

Mechanism of HDFN

HDFN requires three conditions: the mother must lack a red cell antigen that the fetus carries (inherited from the father), the mother must be alloimmunized (or have naturally occurring IgG, as in ABO HDFN), and the antibody must be of an IgG subclass capable of active transport across the placenta via the neonatal Fc receptor (FcRn). IgM antibodies (such as most examples of anti-I, anti-Lea, and anti-P1) do not cross the placenta and do not cause HDFN regardless of titer. Once maternal IgG crosses into the fetal circulation, it coats antigen-positive fetal red cells, which are then removed primarily by extravascular hemolysis in the fetal spleen and liver. Sustained hemolysis drives fetal reticulocytosis and, in severe cases, extramedullary hematopoiesis, hepatosplenomegaly, hypoproteinemia, and ultimately hydrops fetalis (generalized fetal edema and effusions from severe anemia and heart failure).

Antibodies of Clinical Significance

  • Antibody Typical Severity Key Teaching Point
  • Anti-D Mild to severe Classic cause of severe HDFN; largely preventable with RhIG
  • Anti-c, anti-E Mild to severe Can cause significant HDFN; not covered by RhIG

Anti-K (Kell) Often severe Suppresses erythroid progenitors directly, causing anemia out of proportion to bilirubin/hemolysis markers

Anti-Fya, anti-Jka Mild to moderate Occasionally clinically significant

Anti-A, anti-B (ABO HDFN) Usually mild IgG anti-A,B from group O mothers; weak fetal antigen expression blunts severity

Anti-Lea/Leb, anti-P1, anti-I Not clinically significant Typically IgM and/or antigens poorly developed on fetal cells

Anti-K deserves specialist-level emphasis: because it suppresses red cell production at the progenitor level in addition to causing hemolysis, both maternal titer and amniotic fluid bilirubin (delta OD450) correlate poorly with fetal anemia severity, so management guidelines lower the critical titer threshold and, in some protocols, recommend proceeding directly to Doppler surveillance regardless of titer.

ABO HDFN vs. Rh HDFN

ABO HDFN is common (occurring in a meaningful fraction of group O mother/group A or B infant pairings) but is rarely severe, because A and B antigens are weakly expressed on fetal and neonatal red cells, are also expressed on other tissues and in secretions (which absorb and neutralize some antibody before it reaches red cells), and the fetal red cell membrane is less rigid, resisting complement-mediated damage. Clinically, ABO HDFN presents as early neonatal jaundice with a weakly positive or negative direct antiglobulin test (DAT) and spherocytes on the peripheral smear, and it rarely causes significant fetal anemia or hydrops. By contrast, unresolved Rh(D) or Kell alloimmunization can progress to severe fetal anemia and hydrops, and typically does not affect a first pregnancy (the sensitizing event) but threatens subsequent pregnancies carrying an antigen-positive fetus.

Prenatal Detection and Surveillance

Every pregnant patient receives an antibody screen (indirect antiglobulin test) at the first prenatal visit, repeated around 28 weeks for D-negative patients before RhIG administration. If a clinically significant antibody is identified, the workup proceeds as follows:

Determine paternal antigen status/zygosity or use cell-free fetal DNA (cffDNA) from maternal plasma to noninvasively genotype the fetus for the relevant antigen (RHD genotyping in particular has high sensitivity and specificity and avoids invasive procedures).

If the fetus is antigen-positive or antigen status is unknown, perform serial maternal antibody titers every 2-4 weeks.

Compare each titer to the laboratory's critical titer - conventionally 1:16 for most clinically significant antibodies, but a lower threshold of 1:4 for anti-K given its erythrosuppressive mechanism. A rise of more than one dilution between specimens run in parallel is considered significant.

Once the critical titer is reached (or immediately, regardless of titer, if there is a history of a prior affected pregnancy or a Kell antibody), begin weekly MCA-PSV Doppler surveillance , typically starting by 16-18 weeks gestation.

An MCA-PSV at or above 1.5 multiples of the median (MoM) for gestational age indicates a high probability of moderate-to-severe fetal anemia (sensitivity roughly 86%, specificity roughly 71%) and warrants cordocentesis (percutaneous umbilical blood sampling) to directly measure fetal hemoglobin/hematocrit before deciding on intrauterine transfusion.

Titers lose reliability once a pregnancy has already been affected by HDFN; in that setting, MCA-PSV surveillance is used directly rather than waiting for a titer threshold.

Postnatal Detection

At delivery, cord blood testing typically includes a direct antiglobulin test (DAT) , ABO/Rh type, hemoglobin/hematocrit, and total bilirubin. A positive DAT confirms antibody coating of the infant's red cells; an antibody elution can recover and identify the specific antibody from the infant's cells when maternal antibody specificity was not previously known or needs confirmation. Reticulocytosis, polychromasia, and nucleated red blood cells on the peripheral smear reflect the compensatory marrow response to ongoing hemolysis and help gauge severity alongside serial bilirubin measurements.